• Je něco špatně v tomto záznamu ?

Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial

S. Minisola, F. Marin, DL. Kendler, P. Geusens, CAF. Zerbini, LA. Russo, E. Casado, A. Fahrleitner-Pammer, JJ. Stepan, E. Lespessailles, R. Moericke, A. Bagur, P. Lakatos, P. López-Romero, JJ. Body,

. 2019 ; 14 (1) : 10. [pub] 20190118

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20006634

PURPOSE: Using data from the 2-year, randomized, double-dummy VERO trial, we examined the changes in 25-hydroxy-vitamin D (25[OH]D) concentrations over time, and whether the fracture risk reduction of teriparatide versus risedronate varies by baseline 25(OH)D sufficiency category. METHODS: Postmenopausal women with established osteoporosis received subcutaneous daily teriparatide 20 μg or oral weekly risedronate 35 mg, with concomitant 500-1000 mg of elemental calcium and 400-800 IU/day of vitamin D supplements. Fracture endpoints were analyzed by predefined subgroups of 25(OH)D insufficient and sufficient patients. Heterogeneity of the treatment effect on fractures was investigated by logistic and Cox proportional hazards regression models. RESULTS: At baseline, mean serum 25(OH)D was 31.9 ng/mL in the teriparatide group and 31.5 ng/mL in the risedronate group, and 16.8% and 17.9% of patients, respectively, were 25(OH)D insufficient. At month 6, the mean serum 25(OH)D concentration decreased in teriparatide-treated patients to 24.5 ng/mL (by approximately 23%) but remained relatively constant in risedronate-treated patients (32.2 ng/mL) (p < 0.001). Proportions of 25(OH)D insufficient patients at month 6 were 26.7% and 5.6%, respectively (p < 0.001). The risk reduction with teriparatide versus risedronate for any of the fracture endpoints did not significantly differ between subgroups by 25(OH)D sufficiency status at baseline, with nonsignificant (p > 0.1) treatment-by-25(OH)D interactions in all fracture analyses. CONCLUSIONS: Serum 25(OH)D concentration decreases during teriparatide treatment. Fracture risk reduction with teriparatide versus risedronate did not significantly differ between the two groups of patients defined by baseline 25(OH)D. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01709110 EudraCT Number: 2012-000123-41.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20006634
003      
CZ-PrNML
005      
20200526135030.0
007      
ta
008      
200511s2019 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s11657-019-0561-x $2 doi
035    __
$a (PubMed)30659410
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Minisola, Salvatore $u Department of Internal Medicine and Medical Disciplines, Sapienza Rome University, Viale del Policlinico 151, 00161, Rome, Italy. salvatore.minisola@uniroma1.it.
245    10
$a Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial / $c S. Minisola, F. Marin, DL. Kendler, P. Geusens, CAF. Zerbini, LA. Russo, E. Casado, A. Fahrleitner-Pammer, JJ. Stepan, E. Lespessailles, R. Moericke, A. Bagur, P. Lakatos, P. López-Romero, JJ. Body,
520    9_
$a PURPOSE: Using data from the 2-year, randomized, double-dummy VERO trial, we examined the changes in 25-hydroxy-vitamin D (25[OH]D) concentrations over time, and whether the fracture risk reduction of teriparatide versus risedronate varies by baseline 25(OH)D sufficiency category. METHODS: Postmenopausal women with established osteoporosis received subcutaneous daily teriparatide 20 μg or oral weekly risedronate 35 mg, with concomitant 500-1000 mg of elemental calcium and 400-800 IU/day of vitamin D supplements. Fracture endpoints were analyzed by predefined subgroups of 25(OH)D insufficient and sufficient patients. Heterogeneity of the treatment effect on fractures was investigated by logistic and Cox proportional hazards regression models. RESULTS: At baseline, mean serum 25(OH)D was 31.9 ng/mL in the teriparatide group and 31.5 ng/mL in the risedronate group, and 16.8% and 17.9% of patients, respectively, were 25(OH)D insufficient. At month 6, the mean serum 25(OH)D concentration decreased in teriparatide-treated patients to 24.5 ng/mL (by approximately 23%) but remained relatively constant in risedronate-treated patients (32.2 ng/mL) (p < 0.001). Proportions of 25(OH)D insufficient patients at month 6 were 26.7% and 5.6%, respectively (p < 0.001). The risk reduction with teriparatide versus risedronate for any of the fracture endpoints did not significantly differ between subgroups by 25(OH)D sufficiency status at baseline, with nonsignificant (p > 0.1) treatment-by-25(OH)D interactions in all fracture analyses. CONCLUSIONS: Serum 25(OH)D concentration decreases during teriparatide treatment. Fracture risk reduction with teriparatide versus risedronate did not significantly differ between the two groups of patients defined by baseline 25(OH)D. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01709110 EudraCT Number: 2012-000123-41.
650    _2
$a senioři $7 D000368
650    _2
$a inhibitory kostní resorpce $x terapeutické užití $7 D050071
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a postmenopauzální osteoporóza $x krev $x komplikace $x farmakoterapie $7 D015663
650    _2
$a osteoporotické fraktury $x etiologie $7 D058866
650    _2
$a kyselina risedronová $x terapeutické užití $7 D000068296
650    _2
$a teriparatid $x terapeutické užití $7 D019379
650    _2
$a vitamin D $x analogy a deriváty $x krev $7 D014807
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Marin, Fernando $u Lilly Research Center Europe, Madrid, Spain.
700    1_
$a Kendler, David L $u University of British Columbia, Vancouver, Canada.
700    1_
$a Geusens, Piet $u Maastricht University Medical Center, Maastricht, The Netherlands.
700    1_
$a Zerbini, Cristiano A F $u Centro Paulista de Investigaçao Clínica, Sao Paulo, Brazil.
700    1_
$a Russo, Luis A $u Centro de Analises e Pesquisas Clínicas LTDA, Rio de Janeiro, Brazil.
700    1_
$a Casado, Enrique $u University Hospital Parc Taulí Sabadell (UAB), Barcelona, Spain.
700    1_
$a Fahrleitner-Pammer, Astrid $u Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria.
700    1_
$a Stepan, Jan J $u Institute of Rheumatology and Faculty of Medicine 1, Charles University, Prague, Czech Republic.
700    1_
$a Lespessailles, Eric $u Regional Hospital, University of Orleans, Orleans, France.
700    1_
$a Moericke, Rüdiger $u Institut Präventive Medizin & Klinische Forschung, Magdeburg, Germany.
700    1_
$a Bagur, Alicia $u Centro de Osteopatías Comlit, Buenos Aires, Argentina.
700    1_
$a Lakatos, Péter $u Semmelweis University Medical School, Budapest, Hungary.
700    1_
$a López-Romero, Pedro $u Lilly Research Center Europe, Madrid, Spain.
700    1_
$a Body, Jean Jacques $u CHU Brugmann, ULB, Brussels, Belgium.
773    0_
$w MED00194989 $t Archives of osteoporosis $x 1862-3514 $g Roč. 14, č. 1 (2019), s. 10
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30659410 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200526135026 $b ABA008
999    __
$a ok $b bmc $g 1525492 $s 1096690
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 14 $c 1 $d 10 $e 20190118 $i 1862-3514 $m Archives of osteoporosis $n Arch Osteoporos $x MED00194989
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Možnosti archivace